Breast-Specific Gamma Imaging (BSGI), or molecular breast imaging, has evolved from a related nuclear medicine imaging procedure of the breast, scintimammography, and both are based on the enhanced uptake of sestamibi in tumors within the breast. For years, scintimammography showed considerable promise to be a strong diagnostic tool in the early detection of breast cancer. However, the limitations of the procedure as performed with large general-purpose gamma cameras did not allow for the reliable detection of sub-centimeter lesions or direct correlation to mammograms, thus limiting the capability of this promising diagnostic tool.
The Dilon 6800 overcomes these limitations and can reliably detect sub-centimeter lesions, down to 3mm, and provide the same views as mammography. Another major benefit of the Dilon system is its compact design and mobility, allowing for same-day evaluation and imaging at the point of care.
January 27, 2026 
